Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion ...Middle East

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily,...

Hence then, the article about dizal announces positive topline phase 3 results from wu kong28 study evaluating oral once daily zegfrovy sunvozertinib vs platinum containing chemo doublet in first line non small cell lung cancer nsclc with egfr exon 20 insertion was published today ( Saturday 21/03/2026 - 02:33 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion )

Also on site :

• The Wailers and The Pogues Confirm Australian Tours Despite Bluesfest Collapse
• Joseph Duggar's Wife Kendra Duggar's Mugshot Revealed After Arrest
• Numbrix 9 - March 21